Last updated: February 19, 2026
What is the current development status of Alisporivir?
Alisporivir, a cyclophilin inhibitor intended for hepatitis C virus (HCV) treatment, was developed by Novartis. Phase 2 trials in 2014 demonstrated promising antiviral activity. However, the drug failed to advance beyond late-stage development, with Novartis discontinuing its clinical program in 2016 due to concerns over safety, specifically hepatotoxicity issues observed in some patients.
As of 2023, no active clinical trials for Alisporivir are ongoing. The development has been discontinued by the original sponsor, and no alternative sponsors have announced plans for re-entry into clinical testing or commercialization.
Why was development halted?
- Safety concerns: Elevated liver enzymes and hepatotoxicity noted in multiple studies.
- Efficacy limitations: While effective against HCV in some genotypes, variability limited broad applicability.
- Market shift: The advent of direct-acting antivirals (DAAs) with higher cure rates and better safety profiles rendered Alisporivir less relevant.
What is the market landscape for HCV therapeutics?
The HCV market has evolved rapidly over the last decade, with DAAs dominating. Key drugs include:
| Drug Name |
Approval Year |
Cure Rate |
Common Side Effects |
Price (per treatment) |
| Sofosbuvir (Sovaldi) |
2013 |
>90% |
Fatigue, headaches |
$84,000 |
| Ledipasvir/Sofosbuvir (Harvoni) |
2014 |
>95% |
Fatigue, nausea |
$94,500 |
| Velpatasvir/sofosbuvir (Epclusa) |
2016 |
>95% |
Headaches, fatigue |
$75,000 |
Market forecasts predict a decline in HCV treatment sales with the transition toward fixed-dose combinations and improved safety profiles. The global HCV drug market was valued at approximately $15 billion in 2022 and is expected to contract to $12 billion by 2027.
Is there potential for Alisporivir in other indications?
No approved drugs targeting cyclophilins currently. Theoretical interest exists for:
- Viral indications: Some preclinical evidence links cyclophilin inhibitors to activity against HIV, HBV, and coronaviruses. Nevertheless, no clinical development for Alisporivir has been reported outside HCV.
- Autoimmune diseases: Due to immunomodulatory effects, potential exists, but evidence remains preliminary.
Development efforts have shifted away from Alisporivir toward newer agents with safer profiles.
What are the strategic implications?
- R&D investment: Likely unattractive given past safety issues and market saturation.
- Partnership opportunities: Limited without significant reformulation or new indications.
- Investment focus: Alternative cyclophilin inhibitors or next-generation broad-spectrum antivirals may offer better prospects.
Key market projections
- The decline of the HCV market persists, driven by treatment standardization and high cure rates with existing DAAs.
- No active pipelines orlicensing deals for Alisporivir are known.
- Companies are concentrating on innovative antiviral platforms, diminishing the likelihood of revived interest in Alisporivir.
Key Takeaways
Alisporivir's development was halted in 2016 due to safety concerns and limited efficacy advantages. The HCV market's evolution favors DAAs with superior safety and effectiveness profiles. The drug currently holds no active clinical development or commercialization plans. Its potential for repurposing in other viral or autoimmune indications remains unsubstantiated, and strategic focus has shifted toward next-generation agents.
FAQ
1. Could Alisporivir re-enter clinical development?
Unlikely without significant safety reformulation and supportive efficacy data, considering past adverse events and market trends.
2. Are there ongoing efforts to develop cyclophilin inhibitors?
Yes, other companies are exploring newer, potentially safer cyclophilin inhibitors for various viral diseases, but not specifically Alisporivir.
3. What replaced Alisporivir in HCV treatment?
Highly effective DAAs like sofosbuvir-based combinations dominate the market with cure rates exceeding 95%.
4. Is there a commercial opportunity for cyclophilin inhibitors outside HCV?
Potential exists but remains speculative; no current pipeline demonstrates active development.
5. How does the safety profile impact drug development choices?
Safety concerns, especially hepatotoxicity, heavily influence progression decisions, rendering drugs with adverse safety signals less viable.
References
[1] Novartis. (2016). Development halt of Alisporivir for hepatitis C. Pharma Business Review.
[2] MarketWatch. (2022). Global hepatitis C market size and forecast.
[3] FDA. (2014). Approvals and safety warnings for hepatitis C therapies.
[4] IMS Health. (2023). Pharmaceutical market analysis report.
